nobsluhelp的部落格

Raritan, NJ (March 31, 2014) - Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient populations, including those at risk for DVT or PE due to a concurrent medical illness. The new studies will include more than 11,000 patients in over 30 countries. With the addition of these studies, the EXPLORER global cardiovascular research program now encompasses eight clinical trials assessing the safety and efficacy of rivaroxaban in high-risk patient populations, including those with chronic heart failure, coronary artery disease and peripheral artery disease. EXPLORER is an integral part of the extensive clinical development program for rivaroxaban, evaluating its use in a broad range of cardiovascular conditions. "Each year in the U.S., more people die from DVT and PE than from motor vehicle accidents, breast cancer and HIV combined," said Anne Hermanowski Vosatka, M.D., Ph.D., FACC, vice president and compound development team leader for XARELTO® at Janssen. "New trials added to the EXPLORER global cardiovascular research program will broaden our understanding of how rivaroxaban might help patients at risk for developing blood clots such as DVT or PE, addressing an urgent unmet need. MARINER is a Phase 3 study designed to evaluate the efficacy and safety of rivaroxaban once-daily compared with placebo to reduce the risk of symptomatic DVT and/or PE due to a concurrent medical illness for up to 45 days after hospital discharge. This study will include approximately 8,000 patients in more than 15 countries. EINSTEIN JUNIOR, including Phase 1, 2a, 2b and 3 clinical trials, will evaluate rivaroxaban according to an age- and body weight-adjusted dosing schedule for the treatment and secondary prevention of DVT and/or PE in pediatric populations. The study program will include at least 150 patients in 20 countries, and is currently enrolling participants for Phase 2 trials. The Phase 3 study is expected to start in September 2014. Please click here for more information. EINSTEIN CHOICE is a Phase 3 study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately 2,850 patients in 31 countries and is currently enrolling participants. Please click here for more information. In total, the global clinical development program for rivaroxaban will include 15 Phase 3 clinical trials, 10 of which are completed. By the time of its completion in 2018, more than 136,000 patients are expected to have participated in the global clinical development program, including those patients assessed in EXPLORER. In addition, Janssen and Bayer recently entered into an agreement with Portola Pharmaceuticals, Inc. to initiate Phase 3 studies evaluating Portola's investigational Factor Xa inhibitor reversal agent, andexanet alpha, for use with XARELTO® in emergency situations, such as for patients with major bleeding or those requiring emergency surgery. The clinical collaboration will be in effect through completion of Phase 3 studies with XARELTO® and any potential U.S. and EU regulatory approval of andexanet alfa. Phase 3 studies are expected to start in the first half of 2014. DVT is a condition in which blood clots form in one of the large, deep veins, usually in the legs. PE is a serious condition that most commonly occurs when part or all of a DVT dislodges and travels to the lung, via the heart, where it can partially or completely block a branch of the pulmonary artery. When PE occurs with large clots, multiple clots or when the patient already has pre-existing heart or lung disease, the event may be fatal. Each year up to 900,000 Americans experience a DVT or PE, resulting in up to 300,000 deaths. The EXPLORER global cardiovascular research program is an integral part of the extensive clinical development program for rivaroxaban, evaluating its use in a broad range of cardiovascular conditions, making it the most studied and broadly indicated oral Factor Xa inhibitor in the world today. COMMANDER-HF is evaluating rivaroxaban in patients with chronic heart failure and significant coronary artery disease who are receiving standard care. The study will include 5,000 patients in 12 countries. Please click here for more information. COMPASS is evaluating rivaroxaban in patients with coronary artery disease or peripheral artery disease. This study includes 20,000 patients across 25 countries and will be conducted in collaboration with the Population Health Research Institute (PHRI) at McMaster University in Hamilton, Ontario, Canada. Please click here for more information. PIONEER AF-PCI is evaluating rivaroxaban in 2,100 patients who have non-valvular atrial fibrillation (NVAF) and are undergoing percutaneous coronary intervention (PCI) with stent placement. The trial is assessing rivaroxaban in combination with dual antiplatelet therapy and when aspirin is not used. Please click here for more information. VENTURE-AF is evaluating the use of rivaroxaban in patients with NVAF undergoing catheter ablation, a procedure that uses energy delivered through catheters to eliminate the abnormal tissue that is causing the arrhythmia. The study will include up to 250 patients in four countries. Please click here for more information. X-VeRT is evaluating patients with atrial fibrillation scheduled for cardioversion - a medical procedure to convert abnormally fast heart rate to a normal rhythm, using electricity or antiarrhythmic medications. The study includes 1,500 patients across 17 countries and will compare rivaroxaban to dose-adjusted vitamin K antagonist. Please click here for more information. XARELTO® works by blocking the blood clotting Factor Xa and does not require routine blood monitoring. To reduce the risk of strokes and blood clots in patients with atrial fibrillation not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO® and warfarin compare in reducing the risk of stroke. To treat patients with deep vein thrombosis (DVT). To treat patients with pulmonary embolism (PE). To reduce the risk of recurrence of DVT or PE following an initial six-month treatment for acute venous thromboembolism. To reduce the risk of blood clots in the legs and lungs of patients who have just had knee replacement surgery. To reduce the risk of blood clots in the legs and lungs of patients who have just had hip replacement surgery. Eight million patients have received XARELTO® worldwide, and more than five million prescriptions have been written for XARELTO® in the U.S. XARELTO® has earned a strong reimbursement profile among oral anticoagulants, with 90 percent of patients on Medicare Part D and 90 percent of commercial patients covered at the lowest branded co-pay. Janssen Research & Development, LLC and Bayer HealthCare together are developing rivaroxaban. For more information about XARELTO®, visit www.xarelto-us.com. The XARELTO® CarePath™ Support Program is a resource designed for healthcare providers, patients and caregivers. Visit www.xareltocarepath.com or call 1-888-XARELTO to learn more about the XARELTO® CarePath™ resources focused on access, education and adherence. XARELTO® is a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO® and warfarin compare in reducing the risk of stroke. XARELTO® is also a prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again. XARELTO® is also a prescription medicine used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery. People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO® lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO®, you may have increased risk of forming a clot in your blood. Do not stop taking XARELTO® without talking to the doctor who prescribes it for you. Stopping XARELTO® increases your risk of having a stroke. If you have to stop taking XARELTO®, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. XARELTO® can cause bleeding, which can be serious, and rarely may lead to death. This is because XARELTO® is a blood thinner medicine that reduces blood clotting. While you take XARELTO® you are likely to bruise more easily and it may take longer for bleeding to stop. Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. Spinal or epidural blood clots (hematoma): People who take a blood thinner medicine (anticoagulant) like XARELTO®, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). If you take XARELTO® and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). XARELTO® is not for patients with artificial heart valves. Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO® if you currently have unusual bleeding. Are allergic to rivaroxaban or any of the ingredients of XARELTO®. Are pregnant or plan to become pregnant. It is not known if XARELTO® will harm your unborn baby. Tell your doctor right away if you become pregnant while taking XARELTO®. If you take XARELTO® during pregnancy, tell your doctor right away if you have bleeding or symptoms of blood loss. Are breastfeeding or plan to breastfeed. It is not known if XARELTO® passes into your breast milk. You and your doctor should decide if you will take XARELTO® or breastfeed. Tell all of your doctors and dentists that you are taking XARELTO®. They should talk to the doctor who prescribed XARELTO® for you before you have any surgery, medical or dental procedure. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way XARELTO® works. Certain medicines may increase your risk of bleeding. St. Ask your doctor if you are not sure if your medicine is one listed above. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. Take XARELTO® exactly as prescribed by your doctor. Do not change your dose or stop taking XARELTO® unless your doctor tells you to. Your doctor will tell you how much XARELTO® to take and when to take it. Your doctor may change your dose if needed. Atrial Fibrillation: Take XARELTO® 1 time a day with your evening meal. If you miss a dose of XARELTO®, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Take XARELTO® once or twice a day as prescribed by your doctor. Take XARELTO® with food at the same time each day. and take XARELTO® 2 times a day: Take XARELTO® as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. and take XARELTO® 1 time a day: Take XARELTO® as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Hip or knee replacement surgery: Take XARELTO® 1 time a day with or without food. If you miss a dose of XARELTO®, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take XARELTO®. Your doctor will decide how long you should take XARELTO®. Do not stop taking XARELTO® without talking to your doctor first. Your doctor may stop XARELTO® for a short time before any surgery, medical or dental procedure. Your doctor will tell you when to start taking XARELTO® again after your surgery or procedure. Do not run out of XARELTO®. Refill your prescription for XARELTO® before you run out. When leaving the hospital following a hip or knee replacement, be sure that you have XARELTO® available to avoid missing any doses. If you take too much XARELTO®, go to the nearest hospital emergency room or call your doctor right away. Please see "What is the most important information I should know about XARELTO®?" above. Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). Please click here for full Prescribing Information, including Boxed Warnings, and Medication Guide. Trademarks are those of their respective owners. At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc., are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information. (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in new product development, including obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; general industry conditions including trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. kchang12@its.jnj. cchan20@its.jnj. This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information. Natalia de nitido en bikini Phone number for yahoo customer service Drum major clip art Search web images Kamagra bydgoszcz Hawaiian floral stencil How to get money on ohmydollz Pligg content management system windows mail Emergency vehicle stencils visio Surviving the applewhites map Breast cancer swollen nodes hurting under armpit Build your own truck canoe rackm Poker tournament flyer template word Cake text art Hardest old school games Twhat are naughty questions to ask a guy Fantasy football team name generator Bangla choda chudir golpo in bengali font Detached garage with breezeway Creative 21st birthday gifts for her Cherish model forum Tom wahls coupons 2012 Cheat happens unlimited account hack Birthday wishes for husband Sample resume for high school students with no work experience Xbox 360 to verizon hotspot 890l Meetandfuckgames username free Fancy way to write kaylee in cursive Can you take a multivitamin and advil Tbank of america theater obstructed views Mama coiendo a su hijo videos Bridgit mendler bikinirigit mendler Visio cash register Head to toe assessment example Two column proofs quizzes Netflix nintendo 3ds code Idiom lesson plans 3rd grade Hard time quotes Vocabulary workshop enhanced edition level b answers unit 13 First grade roots lesson Ladbrokes 49 s latest results Women college poopers Drug information paroxetine Cheap phentermine no hidden cost Dirty text faces and Girly blackberry bold theme Places that prescribe adderall walk in clinics Vacation trip logs Moshling whole chart Dosage prilosec feline Football pep rally theme vs the bengals Nine west outlet alexandria Mario theme notes letters Leo woman compatibility Halo 2 product key 2012 Pharmacy technician objective sample Lake house sound Cross country ascii Juegos gratis de cars Patriots cheerleader mcafee Spencer bottoms fratpad Koc gem hack download with no survey Is it okay to take nyquil and hydrocodone List of water based lotion for face S r smith slides How to make a home made chasity device How to jack off and mom Second hand lawn bowls After school program template Nail technician resume template Emma starr attorney Citibank seattle Vocab workshop level c review units 1 -3 answers Vishal yesudas reception photos Replace run flat tyres Cover letter examples for estheticians Da form 4856 fillable Published poems about softball Can you take loratadine the same time you take oxycodone Craiglist .com. Parejas swingers in mexico Outlook 2007 cannot send using at&t internet Welcome church poem Life and bitchy quotes Kettler xtr1 elliptical cross trainer 1 night in paris watch online night in p Amazing pictures using the keyboard Megyn price breastsegyn price breasts Cute facebook statuses for boyfriendsute facebook statuses for boy Chi omega sheet music Charter porn cable subscription channels Free printable maple leaf pattern Lung cancer stages and symptoms Girlfriend thumbsirlfriend thumbs Gf revenge members Free rick t shirt 24991-b manual El pulpo junkyard\ Contoh database penjualan makanan Bbq invitation template mac Junior powderpuff sayings Mom washing son in bathtub Extreme bob haircut Good morning texts to a man Nike pegasus retro How do i make a fake wedding picture using your own pictures Craftsman rocking chair How to make blank black eyes on meez Bridal pictionary words Forced sissification captions Post-civil war economy Job assignment letter template How to make a teenren s book Greek goddess inspired dress Potato and onion bin woodworking plans Chinese father songs Cerita bokep indonesia Build hammock chair stand Mexican cartel cuts head off Tgood profile names for online dating Thow we met ideas Motorola razr v3x applications Adobe for kiindle fire Green.moneypak scratch card Personality traits of a virgo man Dad jerks son off Dish crew photos Letterkenny shopping centre christmas opening hours Graffiti the name joey Gyno exam university Hotel cewe jakarta Anniversary letters for boyfriend Reinforced concrete structure design Free owl afghan patterns Birthday gift for a middle school relationship Mother son masturbate Pictures of bob hair styles Gloomy the bear coloring pages Proper health history sample Buying a toilet slave Fatigue and nausea Extreme sports bible verses Costco electronic cigarette Oxycodone minimum detection in urine Hello kitty cross stitch pattern Da form 31 for pureedge Daily math practice for 3rd grade Tdares to ask your girlfriend over the phone I miss you texts to send your boyfriend - funny 40th birthday cake Lola the babysitter walkthrough Genetics challenge worksheet Mortal kombat coloring Navy pt boats for salem Character reference letters to a judge Authentic puerto rican sofrito recipe Joint on keyboard Mom jerking dog off Hack a cellphone frer nowack a cellphone frer now Easy capri sun Herpes fingers pictureserpes finger Television x freeview Contemporary chair rail Bedtime stories to tell ur boyfriend Blueprints of gatling gun free Biology textbook online 9th grade Famous dramatic movie monologues for women Parallel tattoo fonts Ratio-oxycocet codeine Happy birthday missing you quotesappy birthday miss Free sims 3 wedding veils Classic football team names Interview freak from freak the mighty Anabolic steroids medical uses Nike womens anti blister dri fit sock Groping in knickers How to join sinaloa cartel Nims 100 hc answersm Submissive wife pictures Senegalese twists indianapolis Tverizon error fp6a Can activesync download junk hotmail Nas-coal misc. debit Writing a work review on yourself Pictionary words about christictionary words about christ Lexapro upset stomach Entocort to prednisone conversion Queen anne sewing table Game cutting of frogs How you diss blood Resume for marketing manager Pharmacy allegation math Progressive table rotation chart Little brother birthday quotes Chola quotes or sayings Aries woman and libra man Birthday message for boyfriend on facebook Class reunion banquet agenda Breaking dawn first chapter online Lost river paoli Beth the bounty hunter sex tape